Responses
Clinical/translational cancer immunotherapy
Original research
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
